147 related articles for article (PubMed ID: 12540056)
1. Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
Loy R; Tariot PN
J Mol Neurosci; 2002 Dec; 19(3):303-7. PubMed ID: 12540056
[TBL] [Abstract][Full Text] [Related]
2. Can lithium or valproate untie tangles in Alzheimer's disease?
Tariot PN; Aisen PS
J Clin Psychiatry; 2009 Jun; 70(6):919-21. PubMed ID: 19573485
[No Abstract] [Full Text] [Related]
3. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
[TBL] [Abstract][Full Text] [Related]
4. Lithium, a potential protective drug in Alzheimer's disease.
Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
7. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
8. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
[TBL] [Abstract][Full Text] [Related]
9. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
10. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
[TBL] [Abstract][Full Text] [Related]
12. Cytoprotection by lithium and valproate varies between cell types and cellular stresses.
Lai JS; Zhao C; Warsh JJ; Li PP
Eur J Pharmacol; 2006 Jun; 539(1-2):18-26. PubMed ID: 16678157
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.
De Sarno P; Li X; Jope RS
Neuropharmacology; 2002 Dec; 43(7):1158-64. PubMed ID: 12504922
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
16. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Tariot PN; Schneider LS; Cummings J; Thomas RG; Raman R; Jakimovich LJ; Loy R; Bartocci B; Fleisher A; Ismail MS; Porsteinsson A; Weiner M; Jack CR; Thal L; Aisen PS;
Arch Gen Psychiatry; 2011 Aug; 68(8):853-61. PubMed ID: 21810649
[TBL] [Abstract][Full Text] [Related]
17. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
18. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
19. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
20. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
